Axsome Therapeutics (AXSM) Receives a Buy from Leerink Partners

In a report issued on March 28, Marc Goodman from Leerink Partners maintained a Buy rating on Axsome Therapeutics (AXSMResearch Report). The company’s shares closed last Tuesday at $39.31.

According to, Goodman is a 3-star analyst with an average return of 2.9% and a 47.3% success rate. Goodman covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co, Amylyx Pharmaceuticals Inc, and Intra-Cellular Therapies.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Axsome Therapeutics with a $91.83 average price target, representing a 154.7% upside. In a report issued on March 28, Mizuho Securities also reiterated a Buy rating on the stock with a $51.00 price target.

See today’s best-performing stocks on TipRanks >>

Axsome Therapeutics’ market cap is currently $1.35B and has a P/E ratio of -10.13.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Axsome Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing novel therapies for the management of central nervous system disorders. Its product candidates include AXS-02 and AXS-06 which are developing for multiple indications. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.

Read More on AXSM:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More